⌕
Nurix Therapeutics · NRIX · Nasdaq
Tenet 85 · Strong
Compare
$14.67−5.23%At closeTenet 85 · Strong
$14.67−0.81 (−5.23%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
$14.99+0.32 (+2.18%)
After hours: Nov 16, 2026, 4:14 PM ET

Nurix Therapeutics (NRIX) Stock

Nurix Therapeutics (NRIX) closed at $14.67 on Nov 16, 2026; its Tenet Score is 85 of 100 against 313 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

19 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$14.67
Nov 16, 2026
Market cap
$1.7B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
6.1×
price ÷ earnings
52-week range
12.01 – 28.23
low → high · as of close, Nov 13, 2026
Tenet Score
85/100
Strong · 313 Healthcare peers

Industry: Drugs

Nurix Therapeutics Inc scores 85/100. Strong. Strongest on value and growth, trading at 6× earnings versus 313 Healthcare peers.

Tenet Score · vs sector

n=313
85/ 100
Strong
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
97
Quality
67
Health
85
Growth
90

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueA+QualityCHealthBGrowthAMomentumA
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
1.7×
price to book value
P/S
2.4×
price to fiscal 2025 sales
ROE
44%
return on equity
Operating margin
−340.2%
fiscal 2025, before interest and tax
Net margin
42.0%
of revenue kept
Current ratio
8.44
current assets to liabilities
Net debt / EBITDA
−3.5×
leverage, net of cash
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Nurix Therapeutics Inc

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyro…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=313) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 84 US ETFs · top wrappers by weightSee all ETFs holding NRIX →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Nurix Therapeutics in?

Nurix Therapeutics is in the Healthcare sector and the Drugs industry.

What is Nurix Therapeutics' Tenet Score?

Nurix Therapeutics' Tenet Score is 85 out of 100, ranked against 313 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.